Healthcare Management: News. Views. Education

1 . 2024

Selection of donors for fecal microbiota transplantation: compulsory public health screening

Abstract

To date, both in Russia and around the world, there is a growing trend of using a new, promising medical technology – fecal microbiota transplantation (FMT) – a method that is based on the introduction of healthy fecal material from a donor to a recipient in order to restore the disturbed intestinal microbiota of the latter. The selection of a healthy donor for FMT is not only one of the key factors for the success of the procedure as such, but also implements a thorough screening of the health of a volunteer – a potential donor of fecal microbiota. The presented work reveals these aspects.

The study included 73 healthy volunteers, only 4 people met the selection criteria for FMT donation as a result of the screening, which was 1.6%. The creation of fecal microbiota biobanks with samples obtained from donors who have undergone a thorough, rigorous screening procedure can be attributed to promising areas of future medicine development.

Keywords:fecal microbiota transplantation; population health screening; biobank; stool analysis; microbiota

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

Сontribution. Literature review – Gospodarik A.V., Prokhorova N.D.; search for study participants – Gospodarik A.V.; writing the text of the manuscript – Gospodarik A.V., Prokhorova N.D.; analysis of the results obtained – Gospodarik A.V.; statistical analysis of the results – Prokhorova N.D.; concept of the study, final editing of the manuscript text – Bespyatykh J.A.

For citation: Gospodaryk A.V., Prokhorova N.D., Bespyatykh J.A. Selection of donors for fecal microbiota transplantation: compulsory public health screening. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VSHOUZ [HEALTHCARE MANAGEMENT: News, Views, Education. Bulletin of VSHOUZ]. 2024; 10 (1): 92–103. DOI: https://doi.org/10.33029/2411-8621-2024-10-1-92-103 (in Russian)

References

1. Goloshchapov O.V., Olekhnovich E.I., Sidorenko S.V., Moiseev I.S., Kucher M.A., Fedorov D.E., et al. Long-term impact of fecal transplantation in healthy volunteers. BMC Microbiol. 2019; 19 (1): 312. DOI: https://doi.org/10.1186/s12866-019-1689-y PMID: 31888470; PMCID: PMC6938016.

2. Akin’shina A.I., Smirnova D.V., Zagaynova A.V., Makarov V.V., Yudin S.M. Prospects for the use of microbiota correction methods in the treatment of inflammatory bowel diseases. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2019; 29 (2): 12–22. DOI: https://doi.org/10.22416/1382-4376-2019-29-2-12-22 (in Russian)

3. Vasil’ev A.N., Goryachev D.V., Gavrishina E.V., Niyazov R.R., Seliverstov Yu.A., Digtyar’ A.V. Transplantation of fecal microbiota: possible therapeutic approaches and issues of legal regulation. BIOpreparaty. Profilaktika, diagnostika, lechenie [BIOpreparations. Prevention, Diagnosis, Treatment]. 2015; 2 (54). URL: https://cyberleninka.ru/article/n/transplantatsiya-fekalnoy-mikrobioty-vozmozhnye-terapevticheskie-podhody-i-voprosy-pravovogo-regulirovaniya (date of access August 22, 2023). (in Russian)

4. Gulati A.S., Nicholson M.R., Khoruts A., Kahn S.A. Fecal microbiota transplantation across the lifespan: balancing efficacy, safety, and innovation. Am J Gastroenterol. 2023; 118 (3): 435–9. DOI: https://doi.org/10.14309/ajg.0000000000002167 Epub 2022 Dec 29. PMID: 36580630; PMCID: PMC9992015.

5. Shcherbakov P.L., Belova N.D., Generozov E.V., Zhgun E.S., Ivanova O.I., Il’ina E.N., et al. Application of fecal transplantation in the treatment of diseases of the digestive tract (the first clinical experience). Doctor.Ru. 2019; 3 (158): 40–6. DOI: https://doi.org/10.31550/1727-2378-2019-158-3-40-46 (in Russian)

6. Melikhov O.G., Tsepova E.A. Legal regulation of relations with patients and volunteers in clinical trials. Remedium. 2017; (11). URL: https://cyberleninka.ru/article/n/pravovoe-regulirovanie-otnosheniy-s-patsientami-i-dobrovoltsami-v-klinicheskih-issledovaniyah (date of access August 22, 2023). (in Russian)

7. Bibbò S., Settanni C.R., Porcari S., Bocchino E., Ianiro G., Cammarota G., et al. Fecal microbiota transplantation: screening and selection to choose the optimal donor. J Clin Med. 2020; 9 (6): 1757. DOI: https://doi.org/10.3390/jcm9061757 PMID: 32517023; PMCID: PMC7356099.

8. Woodworth M.H., Carpentieri C., Sitchenko K.L., Kraft C.S. Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review. Gut Microbes. 2017; 8 (3): 225–37. DOI: https://doi.org/10.1080/19490976.2017.1286006 Epub 2017 Jan 27. PMID: 28129018; PMCID: PMC5479407.

9. Yakupova A.A., Abdulkhakov S.R., Safin A.G., Alieva I.M., Oslopova Yu.V., Abdulkhakov R.A. Fecal microbiota transplantation: criteria for donor selection, preparation and storage of biomaterial. Terapevticheskiy arkhiv [Therapeutic Archive]. 2021; 93 (2): 215–21. DOI: https://doi.org/10.26442/00403660.2021.02.200615 (in Russian)

10. Pavletic A.J. Why knowing healthy controls matters. Int J Clin Pract. 2020; 74 (1): e13424. DOI: https://doi.org/10.1111/ijcp.13424 Epub 2019 Oct 14. PMID: 31573729; PMCID: PMC6980973.

11. Drapkina OM, Samorodskaia IV. Screening: terminology, principles and international experience // Profilakticheskaya Meditsina. 2019; 22 (1): 90‑97. DOI: https://doi.org/10.17116/profmed20192201190 (in Russian)

12. Deiteren A., Coenen E., Lenders S., Verwilst P., Mannaert E., Rasschaert F. Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes. Clin Transl Sci. 2021; 14 (6): 2450–60. DOI: https://doi.org/10.1111/cts.13113 Epub 2021 Aug.

13. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017; 66 (4): 569-580. DOI: https://doi.org/10.1136/gutjnl-2016-313017 Epub 2017 Jan 13. PMID: 28087657; PMCID: PMC5529972.

14. Bénard MV, de Bruijn CMA, Fenneman AC, Wortelboer K, Zeevenhoven J, Rethans B, Herrema HJ, van Gool T, Nieuwdorp M, Benninga MA, Ponsioen CY. Challenges and costs of donor screening for fecal microbiota transplantations. PLoS One. 2022 Oct 20; 17 (10): e0276323. DOI: https://doi.org/10.1371/journal.pone.0276323 PMID: 36264933; PMCID: PMC9584411.

15. Chen J., Zaman A., Ramakrishna B., Olesen S.W. Stool banking for fecal microbiota transplantation: methods and operations at a large stool bank. Front Cell Infect Microbiol. 2021; 11: 622949. DOI: https://doi.org/10.3389/fcimb.2021.622949 PMID: 33937092; PMCID: PMC8082449.

16. Porcari S., Benech N., Valles-Colomer M., Segata N., Gasbarrini A., Cammarota G., et al. Key determinants of success in fecal microbiota transplantation: from microbiome to clinic. Cell Host Microbe. 2023; 31 (5): 712–33. DOI: https://doi.org/10.1016/j.chom.2023.03.020 PMID: 37167953.

17. Gospodarik A.V., Ulakhanova L.A., Esiev S.S., Polyakova E.V., Shansky Ya.D., Bespyatykh Yu.A. The role of genetic markers of drug resistance mef and ermB in the selection of fecal microbiota donors. Vestnik RGMU [Bulletin of RSMU]. 2022; (6): 5–12. DOI: https://doi.org/10.24075/vrgmu.2022.059 (in Russian)

18. Farrell D.J., Morrissey I., Bakker S., Morris L., Buckridge S., Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)- mediated macrolide resistance. J Clin Microbiol. 2004; 42 (2): 764–8. DOI: https://doi.org/10.1128/JCM.42.2.764-768.2004 PMID: 14766850; PMCID: PMC344484.

19. He J., He X., Ma Y., Yang L., Fang H., Shang S., et al. A comprehensive approach to stool donor screening for faecal microbiota transplantation in China. Microb Cell Fact. 2021; 20 (1): 216. DOI: https://doi.org/10.1186/s12934-021-01705-0 PMID: 34838016; PMCID: PMC8626716.

20. Flores G.E., Caporaso J.G., Henley J.B., Rideout J.R., Domogala D., Chase J., et al. Temporal variability is a personalized feature of the human microbiome. Genome Biol. 2014; 15 (12): 531. DOI: https://doi.org/10.1186/s13059-014-0531-y PMID: 25517225; PMCID: PMC4252997.

21. Paramsothy S., Borody T.J., Lin E., Finlayson S., Walsh A.J., Samuel D., et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015; 21 (7): 1600–6. DOI: https://doi.org/10.1097/MIB.0000000000000405 PMID: 26070003.